Compounds > soman
Page last updated: 2024-08-18

soman and ly 293558

soman has been researched along with ly 293558 in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (66.67)24.3611
2020's3 (33.33)2.80

Authors

AuthorsStudies
Apland, JP; Aroniadou-Anderjaska, V; Braga, MF; Figueiredo, TH; Qashu, F; Souza, AP1
Apland, JP; Aroniadou-Anderjaska, V; Braga, MF; Figueiredo, TH; Green, CE; Qashu, F; Swezey, R; Yang, C1
Apland, JP; Aroniadou-Anderjaska, V; Braga, MF; Figueiredo, TH; Long, RP; Prager, EM1
Almeida-Suhett, CP; Apland, JP; Aroniadou-Anderjaska, V; Braga, MF; Figueiredo, TH; Miller, SL; Prager, EM1
Apland, JP; Aroniadou-Anderjaska, V; Braga, MFM; Figueiredo, TH; Pidoplichko, VI; Rossetti, K1
Apland, JP; Aroniadou-Anderjaska, V; Braga, MFM; De Araujo Furtado, M; Figueiredo, TH2
Apland, JP; Aroniadou-Anderjaska, V; Braga, MF; Figueiredo, TH1
Apland, JP; Aroniadou-Anderjaska, V; Braga, MF; Figueiredo, TH; Rossetti, K1

Reviews

1 review(s) available for soman and ly 293558

ArticleYear
Targeting the glutamatergic system to counteract organophosphate poisoning: A novel therapeutic strategy.
    Neurobiology of disease, 2020, Volume: 133

    Topics: Animals; Anticonvulsants; Cholinesterase Inhibitors; Humans; Isoquinolines; Nerve Agents; Neuroprotective Agents; Organophosphate Poisoning; Rats; Receptors, AMPA; Receptors, Kainic Acid; Soman; Status Epilepticus; Tetrazoles

2020

Other Studies

8 other study(ies) available for soman and ly 293558

ArticleYear
The GluK1 (GluR5) Kainate/{alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist LY293558 reduces soman-induced seizures and neuropathology.
    The Journal of pharmacology and experimental therapeutics, 2011, Volume: 336, Issue:2

    Topics: Animals; Chemical Warfare Agents; Electroencephalography; gamma-Aminobutyric Acid; Interneurons; Isoquinolines; Neurodegenerative Diseases; Neurons; Rats; Receptors, AMPA; Receptors, Kainic Acid; Seizures; Soman; Tetrazoles

2011
Efficacy of the GluK1/AMPA receptor antagonist LY293558 against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration.
    The Journal of pharmacology and experimental therapeutics, 2013, Volume: 344, Issue:1

    Topics: Animals; Anticonvulsants; Antidotes; Atropine; Brain; Cholinesterase Inhibitors; Electroencephalography; Fluoresceins; Fluorescent Dyes; Injections, Intramuscular; Isoquinolines; Male; Muscarinic Antagonists; Nerve Degeneration; Oximes; Pyridinium Compounds; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, Kainic Acid; Seizures; Soman; Tetrazoles; Tissue Fixation

2013
LY293558 prevents soman-induced pathophysiological alterations in the basolateral amygdala and the development of anxiety.
    Neuropharmacology, 2015, Volume: 89

    Topics: Animals; Anxiety; Basolateral Nuclear Complex; Isoquinolines; Male; Organ Culture Techniques; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Reflex, Startle; Soman; Tetrazoles

2015
A rat model of nerve agent exposure applicable to the pediatric population: The anticonvulsant efficacies of atropine and GluK1 antagonists.
    Toxicology and applied pharmacology, 2015, Apr-15, Volume: 284, Issue:2

    Topics: Acetylcholinesterase; Animals; Anticonvulsants; Atropine; Chemical Warfare Agents; Cholinesterase Inhibitors; Disease Models, Animal; Hippocampus; Isoquinolines; Male; Nerve Degeneration; Oximes; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Kainic Acid; Seizures; Soman; Status Epilepticus; Tetrazoles

2015
Comparing the Antiseizure and Neuroprotective Efficacy of LY293558, Diazepam, Caramiphen, and LY293558-Caramiphen Combination against Soman in a Rat Model Relevant to the Pediatric Population.
    The Journal of pharmacology and experimental therapeutics, 2018, Volume: 365, Issue:2

    Topics: Animals; Anticonvulsants; Anxiety; Basolateral Nuclear Complex; Behavior, Animal; Child; Cyclopentanes; Diazepam; Disease Models, Animal; Drug Interactions; Humans; Isoquinolines; Male; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Soman; Status Epilepticus; Tetrazoles

2018
Full Protection Against Soman-Induced Seizures and Brain Damage by LY293558 and Caramiphen Combination Treatment in Adult Rats.
    Neurotoxicity research, 2018, Volume: 34, Issue:3

    Topics: Animals; Anticonvulsants; Body Weight; Brain Injuries; Brain Waves; Cholinesterase Inhibitors; Cyclopentanes; Disease Models, Animal; Drug Therapy, Combination; Electroencephalography; Fluoresceins; Fourier Analysis; Isoquinolines; Male; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Seizures; Soman; Tetrazoles; Time Factors

2018
Electroencephalographic analysis in soman-exposed 21-day-old rats and the effects of midazolam or LY293558 with caramiphen.
    Annals of the New York Academy of Sciences, 2020, Volume: 1479, Issue:1

    Topics: Animals; Antidotes; Cyclopentanes; Electrocardiography; Isoquinolines; Male; Midazolam; Nerve Agents; Rats; Rats, Sprague-Dawley; Soman; Status Epilepticus; Tetrazoles

2020
Delayed tezampanel and caramiphen treatment but not midazolam protects against long-term neuropathology after soman exposure.
    Experimental biology and medicine (Maywood, N.J.), 2023, Volume: 248, Issue:7

    Topics: Animals; Anticonvulsants; Brain; Brain Injuries; Female; Male; Midazolam; Nerve Agents; Rats; Seizures; Soman; Status Epilepticus

2023